Advertisement
Screener

Standard BioTools Inc. (LAB) Material Contracts, 2021

Standard BioTools Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2021-11-09: Form 10-Q; Exhibit 10.1; Description Amendment dated September 29, 2021 to Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020, February 18, 2021, and May 10, 2021..
  • 2021-08-06: Form 10-Q; Exhibit 10.5; Description Terms and Conditions of Employment for Colin McCracken, effective June 26, 2021..
  • 2021-08-06: Form 10-Q; Exhibit 10.4; Description Repatriation Agreement with Colin McCracken dated June 16, 2021..
  • 2021-08-06: Form 10-Q; Exhibit 10.3; Description Lease Agreement dated June 8, 2021 between Fluidigm Singapore Pte. Ltd. and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust..
FiledFormExhibitDescription
2021-11-0910-Q10.1Amendment dated September 29, 2021 to Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020, February 18, 2021, and May 10, 2021.
2021-08-0610-Q10.5Terms and Conditions of Employment for Colin McCracken, effective June 26, 2021.
2021-08-0610-Q10.4Repatriation Agreement with Colin McCracken dated June 16, 2021.
2021-08-0610-Q10.3Lease Agreement dated June 8, 2021 between Fluidigm Singapore Pte. Ltd. and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust.
2021-08-0610-Q10.2Lease Agreement dated November 19, 2020 between Fluidigm Singapore Pte. Ltd. and HSBC Institutional Trust Services (Singapore) Limited as Trustee of Ascendas Real Estate Investment Trust.
2021-08-0610-Q10.1Amendment dated May 10, 2021 to Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020 and February 18, 2021.
2021-08-058-K10.1Fourth Amendment to Loan and Security Agreement, dated as of August 2, 2021, between Fluidigm Corporation and Silicon Valley Bank.
2021-05-258-K10.1Fluidigm Corporation 2011 Equity Incentive Plan, as amended effective May 25, 2021.
2021-05-0710-Q10.1Contract by and between the National Institutes of Health and the registrant effective as of July 30, 2020, as amended September 28, 2020 and February 18, 2021.
2021-02-2510-K10.31Offer Letter to Nick Khadder dated April 6, 2020.
2021-02-2510-K10.30Offer Letter to Colin McCracken dated April 12, 2019.
2021-02-2510-K10.2BSecond Amendment to Lease between AP3-SF3 CT North, LLC and Fluidigm Corporation, dated February 25, 2020.

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01